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ABSTRACT 
Introduction: This work investigates whether to 
conduct a medical study from the point of view 
of the expected net benefit taking into account 
statistical power, time and cost. The hypothesis 
of this paper is that the expected net benefit is 
equal to zero. Methods: Information were obtain- 
ed from a pilot medical study that investigates 
the effects of two diagnostic modalities, magne- 
tic resonance imaging (MRI) and computerized 
axial tomography scanner (CT), on patients with 
acute stroke. Statistical procedure was applied 
for planning and contrasting equivalence, non- 
inferiority and inequality hypotheses of the stu- 
dy for the effectiveness, health benefits and costs. 
A statistical simulation model was applied to 
test the hypothesis that conducting the study 
would or not result in overall net benefits. If the 
null hypothesis not rejected, no benefits would 
occurred and therefore the two arms-patterns of 
diagnostic and treatment are of equal net bene- 
fits. If the null hypothesis is rejected, net bene- 
fits would occur if patients are diagnosed with 
the more favourable diagnostic modality. Re- 
sults: For any hypothesis design, the expected 
net benefits are in the range of 366 to 1796 per 
patient at 80% of statistical power if conducting 
the study. The power depends on the monetary 
value available for a unit of health improvement. 
Conclusion: The statistical simulations suggest 
that diagnosing patients with CT will provide 
more favourable health outcomes showing sta- 
tistically significant expected net benefits in 
comparison with MRI. 
 
Keywords: Statistics; Simulation; Hypothesis  
Testing; Expected Net Benefits 
1. INTRODUCTION 
As a general rule private and public researchers in 
medicine and health care, such as medical or pharmaceu- 
tical companies, centers for research and development, 
can be assumed to decide whether or not to carry out a 
study on the basis of the anticipated net benefits of health 
improvements obtained by a product or new medical 
indication. Health system organizations, link (or should 
link) their decisions to the expected future benefits in 
terms of patient’s health improvements and cost savings. 
All parties, however, are likely to consider the cost of 
reaching the expected benefits, such as the cost of the 
study, and they are usually interested in shortening the 
study duration as much as possible, since this will mean 
that an effective diagnosis or treatment will be available 
sooner thus contributing to health improvement and in- 
creasing the time of marketing their product exclusively 
and, hence, the product’s lifecycle benefits. Obtaining 
statistically significant evidence of the superiority, equi- 
valence or non-inferiority of a given modality of diagno-
sis and treatment in relation to other modality increases 
their chances of their application in clinical practice. 
Optimal clinical studies design will avoid unnecessary 
use of resources and increase benefits. Some knowledge 
and information, gathered from the execution of studies, 
can positively contribute toward improving the results of 
such trials. A clinical trial can be viewed as an uncertain 
experiment whose design depends on the problem being 
addressed. Some studies fail to answer the questions that 
need to be addressed [1-3] due to design issues, which 
mean that the resources used are wasted. Conventional 
statistical methods for designing clinical studies are 
widely used to make decisions, basically, on the sample 
size or power requirements used to test the hypothesis 
that there is a difference between two options. These 
models do not take into account the future costs and 
benefits of the decisions that for example might follow  
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study findings; instead they rely on arbitrary decision 
criteria. Other methods have been used with similar ob- 
jectives [4-8], but the authors applied those assuming 
deterministic relationships and so only point results 
could be assessed, which do not take into account vari- 
ability and uncertainty involved in the decisions. 
Patel and Ankolekar [9] established a hybrid classi- 
cal-Bayesian model at the design stage to determine the 
sample size while assuming that the data resulting from 
the study were analyzed based on the classical Neyman 
Pearson formula. A combination of the Bayesian and the 
classical approach was developed by Wang and Leung 
[10] and Shao et al. [11] to optimize the power of clini- 
cal studies. Their model combined the traditional statis- 
tical procedures with prior distribution of accepting a 
new treatment. Kikuchi et al. [12] developed a similar 
model which focused on estimating the subsequent dis- 
tribution of treatment response variance. Jiang et al. [13] 
applied simulation to show which design was more effi- 
cient for the maximum tolerated dose in the treatment of 
a cancer disease. Huang et al. [14] used simulation to 
assess a better design for a parallel study design. The 
simulations showed that their suggested design con- 
served the same sample size, had better power, and as- 
signed doses to patients more efficiently.  
A variety of models have been published focusing on 
the cost and benefit but with different objectives. Baker 
and Heidenberger [15] applied the Monte Carlo simula- 
tion to estimate the sample size that maximizes expected 
health benefits based on expected discounted life years 
gained when the decision maker is constrained by the 
cost of the studies. Spiegelhalter and Best [16] developed 
Bayesian approaches to cost-effectiveness based on dis- 
crete-state Markov models with Monte Carlo simulation. 
They used data from a single clinical study and per- 
formed a probabilistic sensitivity analysis based on first 
and second order Monte Carlo simulation concepts that 
were discussed in Brigs and Sculpher [17], because they 
were uncertain about the cost-benefit estimation of their 
study design. As Willan and Pinto [18], we consider the 
monetary value of health benefits multiplying the quality 
of life obtained by society’s willingness to pay for the 
benefits that would result from implementing the supe- 
rior technology as the standard therapeutic option in a 
health system. Using information from a pilot medical 
study, our work addresses whether from the point of 
view of the expected net benefit (ENB) it would have 
made sense to carry out a clinical or medical trial as- 
suming statistical significant result are reached at certain 
errors. In contrast to the previous methods, our model 
can be applied to discrete or continuous outcomes. More- 
over, as we will show later on, it integrates other aspects 
of the study such statistics, e.g. testing hypothesis, eco- 
nomic and, e.g. the cost of search, the rate of enrolment, 
and managements, e.g. number of centers from which 
patients belong. Taking into account variability and un- 
certainty, the overall hypothesis of this work is that the 
expected net benefit that would result from a study is 
equal to zero or not comparing the effectiveness of two 
diagnostic images. 
In Section 2, we first present a brief description of a 
conducted pilot clinical study results, and then we pre- 
sent a brief background of existing statistical procedures 
for testing hypotheses and at the same time to re-estimate 
the resulting power for a given design and sample size. 
Then, giving the information obtained from the pilot trial 
we construct the expected net benefits model that allow 
helping making decisions of the clinical study at design 
stage. The variability and uncertainty of the expected net 
benefits was quantified estimating the probability distri- 
butions. The model is executed many times to simulate 
simultaneously all hypotheses testing of the trial and of 
the expected net benefits. In Section 3, we present the 
results of the simulation model. In Section 4 we discuss 
the methods and the results of this application. 
2. METHODS 
2.1. The Clinical Study 
Information were provided from a pilot randomized 
medical trial that compares the overall consequences in 
term of effectiveness and health benefit of two diagnostic 
options, CT and MRI option as the initial diagnostic test 
for patients with suspected acute stroke [19]. The alter- 
native hypothesis was that patients initially diagnosed 
with MRI would show a 15% more favourable health 
outcome than those diagnosed with CT. The patients 
were recruited from those admitted to a hospital with 
suspected acute stroke. All patients who met the inclu- 
sion criteria were selected for the study. Statistical ana- 
lysis of the severity of the patient’s condition and other 
characteristics such as age and gender showed that there 
were no statistical significant differences between the 
two groups, therefore both groups can be considered si- 
milar based on a clinical judgment. They were diagnosed 
with either MRI or CT and followed-up for three months. 
After sixteen months of recruitment, 160 patients had 
been recruited of whom 130 were included in the study 
and 30 (0.19) were excluded. The Rankin scale assess- 
ment with categorical values (0, 1, 2, 3, 4, 5, and 6) was 
used to evaluate the health state of each patient at the ad- 
mission to hospital. Each patient were subsequently fol- 
lowed-up for a period of three months, at the end her/his 
health state was evaluated again with the Rankin scale. 
Two outcomes were used to value the health states of pa- 
tients: effectiveness and utility. 
2.1.1. Effectiveness 
In order to quantify the effectiveness at the end of the 
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study (three months after they have been diagnosed and 
treated, the categorical variable resulting from using the 
Rankin scales were converted into 3 health states for 
each patient as follows: 1) levels 0 - 2 were considered as 
an independent health state in which patients are as- 
sumed to have normal life, 2) scale levels 3 - 5 were con- 
sidered as a dependent health state in which patients are 
assumed to need health care, and 3) scale level 6 corre- 
sponds to the death health state. The results of the 130 
patients showed that 87 of them had been diagnosed with 
CT, from which a proportion of 0.506 (p2) were in an 
independent health state; the remaining 43 had been diag- 
nosed with MRI, from which a proportion of 0.429 (p1) 
achieved an independent state. 
The results of the effectiveness of the two diagnostic 
options are shown in Table 1. 
The difference in effectiveness, 0.077, illustrates that 
using CT provided a more favourable outcome. The hy- 
pothesis is tested applying (1), the estimated value (0.82) 
is lower than the upper percentile of α, zα (for α = 0.05, zα 
= 1.96), and therefore there was no evidence to reject the 
null hypothesis that there is no difference in effective- 
ness between the two groups. 
2.1.2. Health Benefits 
The health benefits were quantified by converting the 
Rankin scale into an indicator of quality of life that 
ranges from −0.02 (patient is worse than dead state) to 1 
(patient is alive and in very good state) of patients in two 
moments: at the time of admission to hospital (baseline) 
and after three months (end of study) follow-up. The 
conversion of the Ranking scale levels into a quality of 
life index was obtained according to the results of previ- 
ous studies done by Fagan et al. [20] and Pinto et al. [21]. 
Scale level 0 was converted to 0.9, scale level 1 was con- 
verted to 0.68, scale level 2 was converted to 0.47, scale 
level 3 was converted to 0.2, scale level 4 was converted 
to 0.07, scale level 6 was converted to 0 and scale level 5 
was converted to −0.02. Then the within group health 
benefits in utility was calculated as the difference be- 
tween the two measures of utilities (value of quality of 
life at the end minus the value at the diagnostic state) 
within each group of diagnostic, MRI and CT (see Table 
2). 
2.1.3. Costs 
The costs of the trial were: 1) the treatments costs that  
 
Table 1. Observed results on effectiveness after diagnosing 
patients with MRI or CT. 
 MRI (n1 = 43) CT (n2 = 87)
Independence (Rankin < = 2) 0.429 0.506 
Dependence (Rankin 3 - 5) 0.429 0.412 
Death 0.142 0.082 
Table 2. Observed results on cost and benefits of treatment 
after diagnosing patients with MRI or CT. 
 MRI (n1 = 43) CT (n2 = 87) 
 Mean (SD) Mean (SD) 
Costs of treatment 6184 (2413) 6129 (2546) 
Health benefits 0.1123(0.2815) 0.1638 (0.2286) 
 
could be avoided if all patients were moved to the less 
costly diagnostic option, that is, the difference between 
the cost of treatment under CT and MRI (CTC-CMRI); 
these costs were estimated from the data collected in the 
original study (see Table 2), and 2) the cost of complet- 
ing the study until significant results were found. This is 
estimated as the additional cost of the research, consid- 
ered to be 200 monetary units per patient. 
2.1.4. Results 
The pilot trial’s results were analyzed before the plan- 
ned sample was recruited and the outcomes were evalu- 
ated. It happened because the initial results indicate that 
effectiveness associated with CT is higher than MRI, the 
time results obtained from the recruited patients so far 
suggested that further investigation’s expected duration 
to reach statistical significance in effectiveness exceeds 
the time originally planned for the whole research. Based 
on this initial results, there was no change in the actual 
practice (patients continued be diagnosed with MRI or 
CT), no additional research expenditures were needed 
but there will be no benefits from adopting the best op- 
tion taking into account their effectiveness, health bene- 
fits and cost saving. However, the money invested in the 
study was somehow wasted, as no useful information 
was used to provide evidence on the best option. The de- 
cision made may not be totally accurate since not reject- 
ing the null difference is not evidence of null difference. 
Moreover, the non-significant result might indicate that 
the inequality design of the trial was not appropriate, and 
might have been designed as equivalence or non-inferi- 
ority designs in effectiveness as primary outcome and 
gathering information on health benefits. 
2.2. The Model 
2.2.1. The Statistical Process for Inequality  
Design 
Suppose that a protocol for a double blind randomized 
clinical trial is designed in order to compare the effects 
of two diagnostic products (two diagnostic images), MRI 
and CT on patients with a given disease. In order to test 
on whether or not the effectiveness of the two products is 
or not equal, in the case of comparing two proportions, 
two-sided hypothesis  versus  0 2 1: π π 0H  
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1 2 1  are planned assuming α and β. A sam- 
ple of patients, N, recruited from the population were 
assigned randomly either to MRI or to CT, in which the 
probabilities that an individual has a successful outcome 
is designated as p1 and p2, respectively. As soon as the 
data are available from the trial for evaluation, a test sta- 
tistic can be applied to compare two proportions of suc- 
cess. As in inequality design, using the test statistic with 
the information of the pilot trial we would obtain the 
observed value of the statistic as follow: 
: π π 0H   MRI provides more favourable outcome. If the resulting 
value of zˆ  is lower than −z1−α/2 and higher than −z1−α/2 
(1.96, α = 0.05) or p-value is higher than α, the null hy- 
pothesis is not rejected with the conclusion that there is 
not enough evidence that one of the associated diagnostic 
provides more favourable outcome. 
After providing the success probabilities obtained 
from the pilot trial, the sample size of n1 and n2 that are 
necessary for the new trial can be calculated using for- 
mula 2 taking into account α, β or power. 
Openly accessible at  
  2 12 1 0,1SE
p pz N
p p
      
1 /2 2 1 2 1
2 1
1 /2
SE
Power 1 prob
SE
ˆ1 rob
z p p p p
Z
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p Z z z




        
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(2) 
         (1) ˆ
where, 
     1 1 2 22 1
1 2
1 1p p p p
p p
n n
     SE
Suppose that n1 = 650, n2 = 650 (assuming n1 = n2), p1 
= 0.429, p2 = 0.506 (obtained from the Trial). Applying 
(1) zˆ  = 2.8 (p-value = prob (Z > zˆ ) = 0.0026) indi- 
cates that there is enough evidence to reject the null hy- 
pothesis at significant level of 0.0026. The power of the 
trial, 1 − β, is expected to be as initially planned (e.g. 
80%): 
If the resulting value of zˆ  is higher than z1-α/2 (=1.96, 
α = 0.05) or p-value is smaller than α, the null hypothesis 
is rejected with the conclusion that CT provides more 
favourable outcome. If the resulting value of zˆ  is lower 
than −z1−α/2 (= −1.96, α = 0.05) or p-value is smaller than α, the null hypothesis is rejected with the conclusion that  
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 
 
   
 
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 
Power
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SE 0.506 1 0.506 0.429 1 0.429
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Now, suppose that (n1 = 490) <> (n2 = 980) and applying (2), the expected power of 0.8 would be reached assuming 
unequal allocation as follow: 
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individual has a successful outcome is designated as p1 
and p2, respectively. As soon as the data are available 
from the trial for evaluation, a statistical test can be ap- 
plied to compare two proportions of success. Thus, using 
the test statistic with the information of the pilot trial we 
would obtain the observed value of the statistic as fol- 
low: 
2.2.2. The Statistical Process for Equivalence  
Design 
Suppose that a protocol for a double blind randomized 
clinical trial is designed in order to compare the effects 
of two medical products (two diagnostic images), MRI 
and CT on patients with a given disease. In order to test 
on whether or not the effectiveness of the two products is 
equivalent, in the case of comparing two proportions, the 
equivalence hypotheses 0 2 1: π πH     and 
 
 
2 1
2 1
0.15 0.077ˆ 2.8
SE 0.026
p p
z
p p
       
1 2 1: π πH     are planned. A sample of patients, N, 
recruited from the population were assigned randomly 
either to MRI or to CT, in which the probabilities that an  
Since  > z1-α/2, or p-value is smaller than α the hy- 
pothesis of inequivalence is rejected. Applying the two 
zˆ
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sided confidence interval for the observed difference as- 
suming acceptable margin of difference Δ, if the re- sult-
ing two limits of the confidence interval lie within the 
range [−Δ, +Δ], the hypothesis of inequivalence is re- 
jected, and otherwise, is accepted. 
Suppose that n1 = 730, n2 = 730 (n1 = n2), p1 = 0.429, 
p2 = 0.506, Δ = 0.15, applying (2) the power is expected 
to be: 
 
 
     
 
2 1
2 1
0.15 0.077Power 1 prob 1.96 1 prob 1.96
SE 0.506 1 0.506 0.429 1 0.429
730 730
1 prob 1.96 2.8 1 prob 0.84 0.8.
p p
Z Z
p p
Z z
                        
           
 
Now, suppose (n1 = 550) <> (n2 = 1100) and applying (2), the expected power of 0.8 would be reached assuming un- 
equal allocation. 
 
 
 
   
 
2 1
2 1
0.15 0.506 0.429
Power 1 prob 1.96 1 prob 1.96
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1100 550
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2.2.3. The Statistical Process for Non-Inferiority  
Design 
Suppose that a protocol for a double blind randomized 
clinical trial is designed in order to compare the effects 
of two medical products (two diagnostic images), MRI 
and CT on patients with a given disease. In order to test 
on whether or not CT would provide worse outcome than 
MRI, in the case of comparing two proportions, the one 
sided non-inferiority hypotheses 0 2 1: π πH      
and 1 2 1  are planned. A sample of patients, 
N, recruited from the population was assigned randomly 
either to MRI or to CT, in which the probabilities that an 
individual has a successful outcome is designated as p1 
and p2, respectively. As soon as the data are available 
from the trial for evaluation, a test statistic can be applied 
to compare two proportions of success. Using formula  
: π πH   
(2), we will be able to calculate the sample size or power 
for equal and unequal allocation. 
Suppose that n1 = 578, n2 = 578 (n1 = n2), p1 = 0.429, 
p2 = 0.506, Δ = 0.15, Applying (1) assuming non-inferi- 
ority hypothesis. 
 
 
2 1
1
2 1
0.15 0.077ˆ ˆ2.8. Since ,
SE 0.026
p p
z z
p p
z 
        
the hypothesis of inferiority is rejected. Using the two 
sided confidence interval for the observed difference 
assuming acceptable margin of difference Δ. If the re- 
sulting low limit of the confidence interval is higher than 
the negative margin of [−Δ, +Δ], the hypothesis of the 
inferiority is rejected, and otherwise, is accepted. 
Applying (2) the power is expected to be 
 
 
     
 
2 1
2 1
0.15 0.077Power 1 prob 1.645 1 prob 1.645
S 0.506 1 0.506 0.429 1 0.429
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E p p
Z z
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           
 
Now, suppose (n1 = 420) <> (n2 = 860) and applying (2), the expected power of 0.8 would be reached assuming un- 
equal allocation. 
 
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 
2 1
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2.2.4. The Expected Net Benefit 
The analysis addresses whether from a health system’s 
perspective it would make sense to conduct a clinical 
study, considering the expected net benefit (ENB) for the 
health system. We assume that the cost for the health 
system would consist of the cost of completing the study, 
while the benefits are defined as the health benefits and 
cost savings that would be accrued, assuming a statisti- 
cally significant result was reached. The analysis, how- 
ever, does not consider the potential administrative costs 
of research or any cost related to implementing the deci- 
sion of changing the diagnostic patterns in line with the 
study recommendations. Moreover, the CT is a dominant 
option from a cost-effectiveness perspective, it is less 
costly (see Table 2) and has a better health outcome than 
MRI (see Tables 1 and 2). However, this is not confir- 
mative results because the pilot study did not provide 
evidence statistically significant of superiority of any of 
the two diagnostic images. 
The ENB hypothesis also requires an assessment in 
monetary terms of the future health benefits likely to be 
obtained by using the superior diagnostic modality on all 
patients, which in the context of this work the health 
benefits were quantified by estimating the gain in utility 
as the difference between the two measures of utilities 
corresponding to CT and MRI. The resulting difference 
was multiplied by a cost, which is the amount of willing 
to pay per unit of quality of life. The amount is approxi- 
mately 30,000 monetary units that have often been as- 
sumed as a reasonable cost-effectiveness threshold for 
accepting a new medical device in the health system [21]. 
Taking into account these considerations, two-sided hy- 
pothesis 0  and 1  are planned 
to test whether the ENB is or not zero assuming two 
types of errors α and β. A sample of patients, N (n1 + n2), 
recruited from the population were assigned randomly 
either to MRI or to CT, in which the probabilities that an 
individual has a successful outcome is designated as p1 
and p2, respectively. As soon as the data are available 
from the trial for evaluation, testing this hypothesis, we 
estimate the ENB that would result from integrating the 
power estimated with time, costs and health benefits. If 
ENB is lower than z1-α/2 and higher than−z1−α/2 (z1−α/2 = 
1.96, α = 0.05) or p-value is higher than α, the null hy- 
pothesis is not rejected with the conclusion that there is 
not enough evidence of net benefits, otherwise, the hy- 
pothesis is rejected and we conclude that it there is statis- 
tical evidence of net benefits using MRI or CT diagnostic 
modalities. If the ENB is positive then the CT provides 
net benefits, otherwise, MRI. The ENB test is based on 
the following model: 
: 0H ENB  :H ENB  0
   
     
CT MRI CT MRI
1 2 1 2
ENB power
1 1 CostS
w U U C C
n n e S t n n 
   
       
   (3) 
where, w is the monetary value of a unit improvement of 
utility, UCT and UMRI are the utilities values of CT and 
MRI option respectively, CCT and CMRI are the cost of 
diagnosing a patient with CT or MRI option respectively, 
lambda is the rate of enrolled patients. The total time of 
the trial as a function of the number of patients, the 
number of centers and the rate of enrolment, that is 
 1 2
1
1 S
n n t
e S 
     
. Thus, the total cost of research is  
calculated as the multiplication of the total time by re- 
search cost per patient. 
To put a simple example, suppose that estimated po- 
wer = 0.12, UCT − UMRI = 0.05, CCT − CMRI = 100, for 
simplicity let 
 1 2
1 2
1 Cost
1
200
S
n n t
e S
n n
 
        (monetary currency)  
Per patient, w = 30,000, then ENB = −32. The ENB is 
negative which means that there will be a loss if the CT 
is applied. However, if 0.8 of power is reached, the ENB 
is positive (926 monetary unit) which means that a net 
benefits are expected if patients are diagnosed with CT 
for any hypotheses design. 
In order to test the hypothesis planned that are or not a 
net benefit would derived from the study, the probability 
distribution of ENB is needed. Simulation will allow 
carrying out the trial as if it comes from real world ex- 
periments, given the statistical design and extracting the 
costs and health benefits from their respective distribu- 
tions, and then to estimate probability curve of positive 
expected net benefits. 
2.3. Simulations 
Following the construction of the model as shown in 
Figure 1, we executed it to simulate results of the trial. 
The inputs of the model are effectiveness, the number of 
enrolled per month, time of follow-up, cost of research 
per month, health benefits, cost of each arm of the study 
including diagnosis and treatment. These inputs were 
used through the simulation according to the patients 
flow shown in Figure 1 in order to simulate the trial and 
estimate the ENB, and hence testing the hypotheses of 
our work. 
The states of the simulation model are:  
1) Population: the population from which a sample of 
patients will be selected. 
2) Arrivals: patients will be admitted to the study site 
such as labs, hospital or other research units. 
3) Inclusion: patients will be included at random ac- 
cording to criteria of inclusion that is modeled in prob- 
abilistic pattern. 
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Figure 1. The simulation of the patients flow, Dep. life: de- 
pendent health state where patients assumed to need health care, 
Indep. life: independent health state where patients assumed to 
have normal life without need health care. 
 
4) Diagnosis test: the included patients in the trial are 
assigned randomly to one of the two diagnoses, CT or 
MRI. 
5) Follow-up states: following the diagnostic, the 
health state of each patient will be valued and classified 
into one of three health states three months later: inde- 
pendent health state (indep. life), dependent health state 
(dep. life) and death state (empty). Those patients who 
died before the end of follow-up are excluded from the 
analysis since there were no data on the cause of death. 
The simulation is run in three steps: 
1) Individual simulation (one patient) 
The model starts when a patient from the population 
arrives to the study centre according to an exponential 
arrivals time. It is screened for subsequent inclusion or 
exclusion. If the patient is included then s/he is randomly 
assigned to either MRI or to CT. After that, the patient is 
randomly moved to one of the three health states (indep. 
life, dep. life, empty). All patient movements are con- 
trolled by their respective probabilities and the random 
probabilities generated from a uniform distribution be- 
tween 0 and 1. 
2) Sample of patients simulation 
In order to estimate variability between patients, the 
previous individual simulation was repeated for a given 
number of patients that are selected from the population 
to participate in the trial. When a number of patients are 
included in MRI and in CT (n1 and n2), the simulation is 
stopped and the number of excluded patients, the number 
of patients assigned to MRI and CT, proportion of pa- 
tients in each model state depending on MRI and for CT, 
are obtained. The cost and benefit for this patient were 
randomly chosen assuming normal distribution of cost 
and health benefits. So that the resulting difference in 
effectiveness, utilities and cost of treatments were calcu- 
lated. 
3) Replications  
In order to estimate variability between samples, the 
second step was repeated 10,000 times, applying 10,000 
different sequences of random numbers. Consequently, 
10,000 different results were generated. So that ten thou- 
sands differences in effectiveness were compared ac- 
cording to the corresponding hypothesis testing. Differ- 
ences in mean cost of treatment and in mean health 
benefits between MRI and CT are also obtained for each 
execution. 
The hypothesis contrast, power and expected net bene- 
fits are processed as follows: 
a) For each replication, the statistical value for the 
inequality hypotheses design was estimated dividing the 
observed mean differences in effectiveness by the ex- 
pected standard error. If the calculated statistic is higher 
than the absolute value of z1−α/2, or the p-value is smaller 
than α, we rejected the null hypothesis, otherwise, we 
accepted it. 
b) For each replication, the statistical value for the 
equivalence hypotheses design was estimated assuming Δ 
= 0.15 is an acceptable margin of difference for equiva- 
lence design. If the calculated statistic lies outside the 
area of [−z1−α/2, +z1−α/2], we reject the null hypothesis of 
non-equivalence, otherwise we accept it. 
c) For each replication, the statistical value for non- 
inferiority design was assuming also Δ = 0.15 is an ac- 
ceptable margin of difference for equivalence hypotheses. 
If the calculated statistic lies outside the area of [−z1−α/2, 
+z1−α/2], we rejected the null hypothesis of inferiority, 
otherwise we accepted it. 
d) In all these hypothesis design, the power is calcu- 
lated as the number of rejecting the null hypothesis di- 
vided by the total number of replications (in this work 
they are 10,000 ENBs). Once the expected power of the 
trial is obtained, the expected net benefits are calculated 
for each replication. The 10,000 ENBs obtained allow 
constructing the empirical distribution of the mean, and 
testing the hypothesis of this work, subsequently, the po- 
wer of ENB is calculated as the number of rejecting the 
that the ENB = 0 divided by 10,000. 
3. RESULTS 
Table 3 shows the results of simulations for the three 
studies hypothesis under the same conditions. It is clear 
that variability (SE) of effectiveness, benefits and costs; 
and their 95% confidence interval ranges decreases as the 
sample size increases. There are statistical significant 
differences comparing the effectiveness and benefits of 
MRI and CT (p < 0.05 at 0.8 of power). There are no 
differences in treatment cost following diagnosing pa- 
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tients with MRI or CT (p > 0.05). The null hypothesis of 
the expected net benefits is rejected since for any design 
the statistical significance level lies below 5% at a power 
higher than 80%. Moreover, the probability of rejecting 
the null hypothesis increases as the amount of monetary 
amount of utilities increases, in which case diagnosing 
patients with CT would be beneficial for the patient and 
the hospital that would apply it (Figure 2). Giving the 
results of the simulated hypotheses, the equivalence hy- 
pothesis is more efficient because the expected power of 
the expected net benefits is the highest. 
Simulations results are similar to the analytical ones, 
confirming the accuracy of power and the expected net 
benefits estimated by the statistical procedure. Moreover 
the parameters estimated with simulation that we know 
they can be also available with conventional statistical 
methods, however, the standard error of ENB and stan- 
dard deviation (within and between groups variability) 
are estimated, and thus the accumulated probability dis- 
tribution of ENB could be obtained. In the case of hy- 
pothesis testing, there is a significant evidence that the 
expected net benefits are higher than zero since that the 
resulting value of observed statistical test is higher than 
the reference one t1−α/2 (for α = 0.05, t0.975) at an estimated 
power of more than 80%. Hence, the probability of bene- 
fits moving patients to the CT or MRI diagnostic modal- 
ity could be taken into account for different trial designs. 
4. DISCUSSION AND CONCLUSION 
Medicine and health care are of our primary concerns. 
The overall objective of our group is to improve the 
health of patients. More specifically, with the help of 
scientists, technologists, developers and industry, our aim 
is to help private and public institution in improving dis- 
ease diagnosis and to predict the most optimal treatment 
pattern for patients. Conducting a research study, in first 
instance, required collecting a sample of patients that are 
the main objects of research. Adequate design and sam- 
ple size of clinical or medical studies would yield to ob- 
tain sufficient evidence from the expected results. 
The overall expected net benefits of a study is an issue, 
in this work, the statistical and the simulation processes 
were applied to plan to a new trial taking into account 
data from conducted pilot trial. The simulation model 
addresses the issue of whether any benefit would be de- 
rived from the medical trial carrying out a larger one 
based on the pilot data in order to test the hypothesis. We 
tested some possible hypotheses designs such as inequal- 
ity, equivalence, non-inferiority. In addition, simulations 
provided us with information on variability of complex 
expected net benefits model, allowing for constructing its 
probability distributions. These results were obtained in 
two steps. First, we modeled the results of the pilot study; 
we extend the study to larger sample sizes. Second, we 
repeatedly tested the hypothesis of the simulated study 
for a given sample size, to assess whether or not to reject 
the null hypothesis of any design, inequality, equivalence 
and non-inferiority estimating the empirical probability 
distributions of the expected net benefits. 
From statistical perspective, with the simulation we 
were able to provide information on the expected net’s 
benefits variability. Concretely, testing the hypothesis of 
 
 
Figure 2. Statistical power of expected net benefits depending on availability of money for a 
unit of health improvement.   
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the expected net benefits needed that variability to be 
estimated, marriaging variability from a range of differ- 
ent probability distributions, assuming independency. 
These variables are, the enrollment time per patient that 
follows the inverse of a probability exponential distribu- 
tion and the mean time distribution of inclusion that fol- 
lows a normal distribution, the number of patients that 
reach the primary outcome of the trial that follows a bi- 
nomial distribution and the mean that follows a normal 
distribution, the differences in utility within and between 
samples that were extracted from two normal distribu- 
tions, the overall cost per patient of the treatment that 
assumed to follow a normal distribution, the overall dif- 
ferences in cost of treatment between the two studied 
arms of the study that were extracted from a normal dis- 
tribution. Marriaging all possible values of each combi- 
nation; and uploading them to the expected net benefits 
function generate the empirical distribution of ENB. 
Having estimated its mean and standard error ended in 
the construction of the statistic that used to test our hy- 
pothesis. 
From probabilistic perspective, with simulation we are 
able to apply this procedure to a range of monetary 
amounts that a hospital would receive from the health 
system for a unit of a patient health improvement, or that 
the health system would pay for a unit of health benefit. 
Assuming that the trial has shown statistical significant 
assuming α and β, a probability curve can be generated 
such as the one produced with this study. Although the 
approach in this paper applied to one site trial; however, 
it can be applied to a multisite trial assuming robustness 
or sensitivity on one or more variables. In the robustness 
case, the underlying assumption is that the number of 
sites does not change the effect on health such as the 
effectiveness or utilities, but might increase or decrease 
the cost per patient. Under the sensitivity assumption, 
including more sites will produce different health effects 
and might change other variables, therefore, the proce- 
dure will marriage them within the overall health effects. 
From generality perspective, the simulation model is 
also can be applied taking into account any hypothesis 
testing. For example, trials that study a continuous vari- 
ables and employ t-test for two means: trials that study 
dependency between several variables applying chi- 
square, studies that compare two variances to confirm 
homogeneity or heterogeneity, analysis that study corre- 
lation or dependency between two variables, or trials that 
test statistical association between a given continuous 
response and a given factor. 
In conclusion, the clinical trial was designed with the 
hypothesis that MRI is more costly than CT but would 
show better health outcomes. According to the results of 
the pilot trial, the CT is a dominant option from a cost- 
effectiveness perspective; it is less costly and has a better 
health outcome than MRI. However, the pilot study did 
not provide evidence statistically significant showing the 
favorability of any of the two diagnostic images. The 
simulated trial for larger sample size shows that for any 
hypothesis design the MRI and CT will generate the 
same cost (p > 0.05) but the CT provides better health 
benefits (p < 0.05). Furthermore, we have shown that the 
expected net benefits per patient will be higher than zero 
statistically significant if CT is used for diagnosing pa- 
tients with suspected acute stroke. Therefore, we can 
conclude that CT works better than MRI. 
Finally, we would like to communicate that our re- 
search is being applied to research studies in order to 
search for optimal trial’s parameters design that will 
maximize the expected net benefits resulting from testing 
the hypothesis assuming two types errors of a (the prob- 
ability of rejecting a hypothesis when it is true), and β 
(the probability of rejecting alternative hypothesis when 
it is true) or the power (the probability of accepting a 
hypothesis when it is true). In our on-going research 
project, it is trying to apply the optimization approach to 
aneurysms data. 
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